Valuation: SpectraCure AB

Market Cap 20.48M 2.15M 1.86M 1.75M 1.59M 2.99M 206M 3.04M 8.01M 103M 8.09M 7.91M 343M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value 9.75M 1.03M 885K 832K 757K 1.42M 98.02M 1.45M 3.81M 49.09M 3.85M 3.77M 163M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.39%
Yield 2024 *
-
Yield 2025 -
1 day+1.48%
1 week-15.17%
1 week 0.03
Extreme 0.0263
0.04
1 month 0.03
Extreme 0.0263
0.04
Current year 0.03
Extreme 0.0263
0.04
1 year 0.03
Extreme 0.0263
0.04
3 years 0.03
Extreme 0.0263
0.04
5 years 0.03
Extreme 0.0263
0.04
10 years 0.03
Extreme 0.0263
0.04
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%-15.17% - - 2.15M
-0.38%-3.10%+32.37%+53.44% 1.45B
0.00%+4.17%-32.80%-48.13% 280M
-1.83%-3.60%-12.30%-47.80% 52.63M
Average -0.18%+0.87%-4.24%-14.17% 594.04M
Weighted average by Cap. -0.36%-0.62%+20.81%+34.49%

Financials

2024 2025
Net sales - -
Net income -23M -2.42M -2.09M -1.96M -1.79M -3.36M -231M -3.41M -8.99M -116M -9.08M -8.88M -385M -56.08M -5.9M -5.09M -4.79M -4.35M -8.18M -564M -8.32M -21.93M -282M -22.14M -21.66M -938M
Net Debt -13.13M -1.38M -1.19M -1.12M -1.02M -1.92M -132M -1.95M -5.13M -66.11M -5.18M -5.07M -220M -10.74M -1.13M -975K -916K -833K -1.57M -108M -1.59M -4.2M -54.06M -4.24M -4.15M -180M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
14/08/26 SEK 0.0274 +1.48% 2,013,745
13/08/26 SEK 0.0270 -5.92% 11,797,089
12/08/26 SEK 0.0287 -18.23% 13,715,785
11/08/26 SEK 0.0351 -2.50% 1,830,134
10/08/26 SEK 0.0360 +11.46% 3,752,388